SOPHiA GENETICS (NASDAQ:SOPH) Stock Price Down 5% - Here's Why

Key Points

• SOPHiA GENETICS shares fell 5% to about $8.47, with trading volume down 87% versus the average session. The stock has a market capitalization of roughly $679 million.
• The company’s latest quarterly results were mixed: revenue of $23.31 million exceeded expectations, but adjusted EPS of $(0.26) missed the consensus estimate of $(0.21). Analysts expect a full-year loss of approximately $0.77 per share.
• Analyst sentiment remains mixed, with three Buy ratings, one Hold and one Sell, resulting in a consensus Hold rating and a $10 price target. Insiders sold 334,842 shares worth about $2.1 million over the past quarter.

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) traded down 5% during trading on Friday . The stock traded as low as $8.45 and last traded at $8.47. Approximately 32,677 shares changed hands during trading, a decline of 87% from the average session volume of 242,677 shares. The stock had previously closed at $8.92.

Wall Street Analysts Forecast Growth

A number of research firms have commented on SOPH. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research increased their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. HC Wainwright boosted their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Finally, Zacks Research upgraded SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, SOPHiA GENETICS presently has a consensus rating of "Hold" and a consensus price target of $10.00.

SOPHiA GENETICS Trading Down 9.3%

The stock has a market cap of $678.71 million, a price-to-earnings ratio of -7.03 and a beta of 0.96. The business's 50 day moving average is $6.46 and its 200 day moving average is $5.43. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The business had revenue of $23.31 million for the quarter, compared to analysts' expectations of $21.72 million. As a group, equities analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other SOPHiA GENETICS news, CEO Ross Muken sold 9,838 shares of the firm's stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.22, for a total value of $51,354.36. Following the completion of the sale, the chief executive officer owned 670,651 shares of the company's stock, valued at approximately $3,500,798.22. This trade represents a 1.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 17,000 shares of the business's stock in a transaction on Friday, August 7th. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00. Following the sale, the insider owned 590,887 shares in the company, valued at $4,307,566.23. The trade was a 2.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 334,842 shares of company stock worth $2,110,215. 4.88% of the stock is owned by corporate insiders.

Institutional Trading of SOPHiA GENETICS

Several large investors have recently bought and sold shares of the company. AXQ Capital LP acquired a new stake in shares of SOPHiA GENETICS during the second quarter worth $119,000. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS during the second quarter worth about $9,809,000. Hennion & Walsh Asset Management Inc. purchased a new position in shares of SOPHiA GENETICS during the 2nd quarter valued at approximately $567,000. Royal Bank of Canada increased its position in shares of SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock worth $96,000 after purchasing an additional 18,781 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in SOPHiA GENETICS during the first quarter valued at approximately $1,772,000. Institutional investors and hedge funds own 31.59% of the company's stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source